SEC Form 4 · accession 0001140361-18-009074
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Officer — Interim CEO · Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2018 | M | 15,211 | $5.46 | A | 50,620 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $5.46 | Feb 15, 2018 | M | 15,211 | D | — | Mar 17, 2026 | Common Stock | 15,211 | 8,598 | D |
Explanation of responses
- F1The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.